Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Wells Fargo & Co — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $227.17 (market cap $29.97B), while Wells Fargo & Co trades at $88.53 (market cap $268.92B). The key difference: Wells Fargo & Co is far larger — about 9× Alnylam Pharmaceuticals, Inc.'s market cap, and Wells Fargo & Co pays a 2.25% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | WFC | |
|---|---|---|
Market Cap | $29.97B | $268.92B |
Sector | Health | Financials |
52-Week High | $491.22 | $96.40 |
52-Week Low | $205.48 | $73.42 |
Enterprise Value | $27.93B | — |
Dividend Yield | — | 2.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $227.12, up 2.68% in the last 24 hours, but technical indicators signal a bearish trend with resistance near $229. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with a net income of $313.75M, though recent Q2 2026 earnings missed estimates. Multiple law firms are investigating potential securities fraud, adding to negative sentiment.
Outlook is mixed: analyst consensus remains bullish with a $370.07 price target, but risks include ongoing legal probes, earnings volatility, and high valuation multiples. The stock faces near-term pressure from bearish technicals and investor caution despite solid fundamental progress.
Wells Fargo (WFC) trades at $88.13, up 0.79% daily, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong profitability with a 25.97% net income margin and ROE of 13.13%, supported by rising revenue and earnings trends. Recent news highlights growth initiatives, including digital innovation and a dividend increase to $0.50 per share.
Outlook remains positive with a consensus price target of $97.64, implying 11% upside, though risks include volatile cash flows and competitive pressures. Analyst sentiment is mixed with 45% buy ratings, while institutional interest grows. Earnings momentum and strategic focus on revenue growth underpin investment appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
